Haoyuan Pharma
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 1
- Haoyuan Pharma’s AI Drug Discovery Strategy Meets Its CDMO Platform
TMTPost reports that Haoyuan Pharma is using its compound inventory and synthesis capabilities to support AI-designed drug candidates through the ABC partnership with Insilico Medicine and Mabwell Biopharma, alongside its MedChemAI screening and customization platform. Haoyuan reported 182,000 molecules in reserve as of June 2026 and operates a Chongqing ADC CDMO facility that opened in March 2025. The report says no disclosed AI-related orders have yet demonstrated commercial demand for this model.
钛媒体 · 🔥 0
Experience and discussion from the community
Share my Haoyuan Pharma experienceAsk about Haoyuan Pharma
Nobody has shared their experience with Haoyuan Pharma yet.